Abstract
Despite the advances with cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy, many people living with cystic fibrosis continue to experience lung infections that are challenging to treat.
New treatment options and clinical trial strategies are essential to fill this urgent unmet medical need.
New treatment options and clinical trial strategies are essential to fill this urgent unmet medical need.
Original language | English |
---|---|
Journal | Journal of Cystic Fibrosis |
Early online date | 23 Nov 2024 |
DOIs | |
Publication status | Early online date - 23 Nov 2024 |
Keywords
- lung infections
- cystic fibrosis
- improved quality of life
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Pulmonary and Respiratory Medicine